BR112022021250A2 - Composição farmacêutica compreendendo l-tri-iodotironina (t3) para o uso no tratamento de hipoxia de tecido e septicemia - Google Patents

Composição farmacêutica compreendendo l-tri-iodotironina (t3) para o uso no tratamento de hipoxia de tecido e septicemia

Info

Publication number
BR112022021250A2
BR112022021250A2 BR112022021250A BR112022021250A BR112022021250A2 BR 112022021250 A2 BR112022021250 A2 BR 112022021250A2 BR 112022021250 A BR112022021250 A BR 112022021250A BR 112022021250 A BR112022021250 A BR 112022021250A BR 112022021250 A2 BR112022021250 A2 BR 112022021250A2
Authority
BR
Brazil
Prior art keywords
treatment
septicemia
pharmaceutical composition
iodothyronine
tri
Prior art date
Application number
BR112022021250A
Other languages
English (en)
Portuguese (pt)
Inventor
Pantos Constantinos
Mourouzis Iordanis
Original Assignee
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A, Ioulia Tseti filed Critical Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A
Publication of BR112022021250A2 publication Critical patent/BR112022021250A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112022021250A 2020-04-21 2021-04-15 Composição farmacêutica compreendendo l-tri-iodotironina (t3) para o uso no tratamento de hipoxia de tecido e septicemia BR112022021250A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (1)

Publication Number Publication Date
BR112022021250A2 true BR112022021250A2 (pt) 2022-12-06

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021250A BR112022021250A2 (pt) 2020-04-21 2021-04-15 Composição farmacêutica compreendendo l-tri-iodotironina (t3) para o uso no tratamento de hipoxia de tecido e septicemia

Country Status (13)

Country Link
US (1) US12673036B2 (cg-RX-API-DMAC7.html)
EP (1) EP4138810A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023538984A (cg-RX-API-DMAC7.html)
KR (1) KR102991384B1 (cg-RX-API-DMAC7.html)
CN (1) CN115996710B (cg-RX-API-DMAC7.html)
AU (1) AU2021258544A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021250A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176106A1 (cg-RX-API-DMAC7.html)
GE (2) GEP20247706B (cg-RX-API-DMAC7.html)
IL (1) IL297398B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013228A (cg-RX-API-DMAC7.html)
WO (1) WO2021214497A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202212502B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
WO1995024919A1 (en) * 1994-03-15 1995-09-21 K.U. Leuven Research & Development New use of growth hormone
US20050059574A1 (en) 2000-12-21 2005-03-17 Irwin Klein Compositions of stable T3 and methodes of use thereof
JP2004525874A (ja) 2000-12-21 2004-08-26 リサスサイテック, インコーポレイテッド 安定したt3の組成物およびその使用方法
US8404281B2 (en) 2009-06-08 2013-03-26 Avant Garde Therapeutics & Technologies Llc Formulations
CN103705497B (zh) 2013-12-11 2015-04-01 武汉威立得生物医药有限公司 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
EP3908272B1 (en) 2019-01-09 2023-03-22 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-triiodothyronine (t3) for use in limiting microvascular obstruction
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
GR1010182B (el) 2020-11-23 2022-03-01 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR1010068B (el) 2020-04-21 2021-09-01 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο

Also Published As

Publication number Publication date
KR102991384B1 (ko) 2026-07-14
ZA202212502B (en) 2024-05-30
IL297398B2 (en) 2026-05-01
IL297398B1 (en) 2026-01-01
IL297398A (en) 2022-12-01
KR20230022839A (ko) 2023-02-16
US12673036B2 (en) 2026-07-07
GEP20247706B (en) 2024-12-10
US20230157982A1 (en) 2023-05-25
AU2021258544A1 (en) 2022-10-27
MX2022013228A (es) 2022-11-14
WO2021214497A1 (en) 2021-10-28
CN115996710B (zh) 2024-06-28
EP4138810A1 (en) 2023-03-01
CA3176106A1 (en) 2021-10-28
JP2023538984A (ja) 2023-09-13
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
Ji et al. The mitochondria-targeted antioxidant MitoQ ameliorates myocardial ischemia–reperfusion injury by enhancing PINK1/Parkin-mediated mitophagy in type 2 diabetic rats
Singbartl et al. Differential effects of kidney–lung cross-talk during acute kidney injury and bacterial pneumonia
Boyer et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk
Ager et al. Clinical update on linezolid in the treatment of Gram-positive bacterial infections
Gálvez et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity
Bucki et al. Bactericidal activity of ceragenin CSA-13 in cell culture and in an animal model of peritoneal infection
Novelli et al. Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice
Marks et al. Sensitization of Staphylococcus aureus to methicillin and other antibiotics in vitro and in vivo in the presence of HAMLET
ES2712656T3 (es) Métodos de administración de dalbavancina para el tratamiento de infecciones bacterianas
US20250213511A1 (en) Bactericidal and virucidal pharmaceutical composition
KR20170095894A (ko) 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP2021523125A5 (cg-RX-API-DMAC7.html)
Cao et al. Glycyrrhizic acid improves tacrolimus‐induced renal injury by regulating autophagy
WO2021231314A1 (en) Methods of treating covid-19 using tetracycline compounds
Murray et al. Nitric oxide and septic vascular dysfunction
MX2026000307A (es) Ligando de proteina para la activacion de fibroblastos y su uso
Sattler et al. Aztreonam compared with gentamicin for treatment of serious urinary tract infections
Zhao et al. SGLT2i continuously prevents cardiac hypertrophy by reducing ferroptosis via AMPK up-regulation
ZA202212502B (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis
GR1010182B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
Zala et al. Enterococcus durans prosthetic valve endocarditis: A previously unreported clinical entity
GR1010068B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
AR129944A1 (es) Uso de compuestos que contienen manganeso para reducir el nivel de ácido úrico en sujetos mamíferos; una composición; un kit y un método de prevención y/o tratamiento
TWI391131B (zh) 3-(2,2,2-三甲基肼)丙酸鹽的新用途
AU2021221064B2 (en) Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]